Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is a promising company with positive growth prospects in the medical aesthetics market, as reflected in its strong Q4 performance with over 600 new accounts and a stable reorder rate. With the launch of Evolysse and the initiation of a large sampling and experience program in Q2, the company is well-positioned to further drive revenue growth. With a healthy balance sheet and access to additional debt, Evolus has the financial flexibility to support its expansion plans. While there are risks such as consumer spending environment and potential regulatory delays, the company's strong product portfolio and growth potential make it a Buy with a $13 price target based on 2.5x 12-24 month sales estimate.

Bears say

Evolus is facing increased competition in the medical aesthetics market, particularly with the launch of its competitor's Voluma and the expected launch of its "Sculpt" filler in 2027. While the company has experienced steady growth in its Jeuveau purchasing accounts and the introduction of Evolysse filler has allowed for product bundling, the company has lower growth expectations for its Evolysse Form and Smooth products. Additionally, the company has faced margin pressure due to product and geography mix shift, offset by expense control. While the company expects to achieve positive adjusted operating income in 2026 and reach adjusted operating income margins of 13%-15% in 2028, there are concerns for sustained growth and profitability in future years.

Evolus (EOLS) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Buy based on their latest research and market trends.

According to 5 analysts, Evolus (EOLS) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.